BACKGROUND: Prostate cancer is the most common noncutaneous malignancy in men in the United States.
Patients with metastatic castration-resistant prostate cancer (mCRPC) may be treated with secondary hormonal therapy or with chemotherapy, and potentially with concomitant corticosteroids. Corticosteroids can help manage the side effects of chemotherapy and secondary hormonal therapy and ameliorate prostate cancer-related symptoms, although corticosteroids are also associated with adverse effects. With an increasing number of available treatment options for mCRPC, evaluating the real-world concomitant use of corticosteroids in this patient population is important.
OBJECTIVE: To evaluate the utilization patterns of corticosteroids for the treatment of patients with mCRPC based on real-world data from 2 large claim databases.
METHODS: This retrospective analysis included medical and pharmacy claims from 2 large publicly available healthcare claims databases covering more than 31 million individuals to identify treatment patterns in adult patients with mCRPC. A total of 2593 patients with mCRPC were identified in data set 1 and 626 patients in data set 2 between 2005 and 2011. The appropriate treatment for castration-resistant prostate cancer (CRPC) was defined as chemotherapy, an antiandrogen, an adrenal androgen blocker, or estrogen. The index date was the date of the first CRPC treatment or the first metastasis diagnosis, whichever occurred later. The observation period spanned from the index date to the end of health insurance eligibility. Study end points included population characteristics, the distribution of mCRPC therapies, and corticosteroid utilization patterns.
RESULTS: The study population came from the 2 data sets and included 3219 men who were treated for mCRPC. Bone and lymph nodes were the predominant metastatic sites. Bicalutamide was the most common secondary hormonal therapy, and docetaxel was the most common chemotherapy used for these patients. Overall, 73.4% of the patients in data set 1 received concomitant corticosteroids, as did 71.6% of patients in population 2 during the entire period from the index date to the end of eligibility date. In addition, 62.8% and 60.4% of patients, respectively, received concomitant corticosteroids during the secondary hormonal therapy period, and 93.8% and 95.1% of patients, respectively, received concomitant corticosteroids during the chemotherapy period. Similar patterns of corticosteroid use were observed across geographic areas of the United States.
CONCLUSION: This study shows consistently similar utilization patterns of corticosteroids in patients with mCRPC in 2 large national databases. Using real-world data to inform concomitant corticosteroid use in the treatment of patients with mCRPC may assist healthcare providers with treatment selection and with sequencing decision. Future research is warranted to investigate evolving treatment options for patients with mCRPC.
Written by:
Lafeuille MH, Gravel J, Grittner A, Lefebvre P, Ellis L, McKenzie RS. Are you the author?
Ms Lafeuille is Senior Economist, Groupe d'Analyse, Ltée, Montreal, Quebec, Canada; Mr Gravel is Economist, Groupe d'Analyse, Ltée, Montreal, Quebec, Canada; Ms Grittner is Economist, Groupe d'Analyse, Ltée, Montreal, Quebec, Canada; Mr Lefebvre is Vice President, Groupe d'Analyse, Ltée, Montreal, Quebec, Canada; Dr Ellis is Associate Director, Janssen Scientific Affairs, Titusville, NJ; Dr McKenzie is Senior Director, Janssen Scientific Affairs, Titusville, NJ.
Reference: Am Health Drug Benefits. 2013 Jul;6(6):307-16.
PubMed Abstract
PMID: 24991366
UroToday.com mCRPC Treatment Section
